Literature DB >> 11344122

Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.

P J Cozzi1, S Malhotra, P McAuliffe, D A Kooby, H J Federoff, B Huryk, P Johnson, P T Scardino, W D Heston, Y Fong.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11344122     DOI： 10.1096/fj.00-0533fje

Source DB:  PubMed          Journal:  FASEB J        ISSN： 0892-6638            Impact factor:   5.191


× No keyword cloud information.
  22 in total

1.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

2.  Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.

Authors:  Tae-Jin Song; David P Eisenberg; Prasad S Adusumilli; Michael Hezel; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

3.  Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Authors:  Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

4.  Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.

Authors:  Michael Mullerad; Bernard H Bochner; Prasad S Adusumilli; Amit Bhargava; Eiji Kikuchi; Chen Hui-Ni; Michael W Kattan; Ting-Chao Chou; Yuman Fong
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

Review 5.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 6.  Gene therapy for cancer treatment: past, present and future.

Authors:  Deanna Cross; James K Burmester
Journal:  Clin Med Res       Date:  2006-09

7.  [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Authors:  B A Hadaschik; K Zhang; A I So; J C Bell; J W Thüroff; P S Rennie; M E Gleave
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

8.  Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma.

Authors:  Hao Liu; Shou-Jun Yuan; Ying-Tai Chen; Yi-Bin Xie; Liang Cui; Wei-Zhi Yang; De-Xuan Yang; Yan-Tao Tian
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

Review 9.  Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy.

Authors:  Kaitlyn J Kelly; Joyce Wong; Yuman Fong
Journal:  Expert Opin Investig Drugs       Date:  2008-07       Impact factor: 6.206

10.  Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.

Authors:  Prasad S Adusumilli; Brendon M Stiles; Mei-Ki Chan; Michael Mullerad; David P Eisenberg; Leah Ben-Porat; Rumana Huq; Valerie W Rusch; Yuman Fong
Journal:  J Gene Med       Date:  2006-05       Impact factor: 4.565
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.